-

10:05:41 PM

IONS Stock News

IONS - Ionis Pharmaceuticals Inc

06/25/22 9:05 AM

Nasdaq : IONS

clinical trial

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™

- Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B- Phase 3 clinical study evaluating b epirovirsen as a monotherapy is anticipated to start in the first half of 2023- GSK to explore potential

RHEA-AI

neutral

06/21/22 2:00 AM

Nasdaq : IONS

clinical trial

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

RHEA-AI

very positive

06/13/22 7:05 AM

Nasdaq : IONS

Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an

RHEA-AI

positive

06/03/22 5:20 AM

Nasdaq : IONS

clinical trial

Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients

Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal

RHEA-AI

neutral

05/12/22 7:05 AM

Nasdaq : IONS

conferences

Ionis to present at RBC Capital Markets Global Healthcare Conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.A live webcast and additional information about this presentation can be

RHEA-AI

neutral

05/04/22 7:00 AM

Nasdaq : IONS

earnings

Ionis reports first quarter financial results and recent business achievements

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements."We are off

RHEA-AI

positive

05/02/22 7:05 AM

Nasdaq : IONS

conferences

Ionis to host 2022 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.The agenda for the event is as follows:- 5:00

RHEA-AI

neutral

04/20/22 7:05 AM

Nasdaq : IONS

earnings

Ionis to hold first quarter 2022 financial results webcast

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4 th at 11:30 a.m. Eastern Time to discuss its first quarter financial

RHEA-AI

neutral

04/04/22 12:15 AM

Nasdaq : IONS

clinical trial

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

- ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated- ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen- Study findings warrant further clinical development of

RHEA-AI

neutral

03/28/22 7:30 AM

Nasdaq : IONS, BIIB

clinical trial

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS) , did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

IONS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ionispharma.com
CeoBrett Monia
Security nameIonis Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees757
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2855 Gazelle Ct
StateCalifornia
CityCarlsbad
Zip92010-6670
CountryUS
Phone17609319200

About Ionis Pharmaceuticals Inc

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.